The Filing Desk

argenx vs BioMarin Pharmaceutical

argenx ARGX · BioMarin Pharmaceutical BMRN · Biotechnology

argenx reported revenue of $4.2 billion in fiscal 2025, 1.3 times BioMarin Pharmaceutical's $3.2 billion in fiscal 2025. argenx's revenue grew 88.6% in its latest year, and BioMarin Pharmaceutical's grew 12.9%. argenx had an operating margin of 24.8%, against 12.7% at BioMarin Pharmaceutical. Free cash flow was $679 million at argenx and $725 million at BioMarin Pharmaceutical.

Side by side

argenxBioMarin Pharmaceutical
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$4.2B$3.2B
Revenue growth88.6%12.9%
Revenue growth a year, last 5 years152.7%11.6%
Gross margin89.4%77.7%
Operating margin24.8%12.7%
Net margin30.4%10.8%
Free cash flow$679M$725M
Free cash flow margin16.0%22.5%
Return on capital—5.8%
Net debt to EBITDA—−2.0x
Dividends and buybacks$0M$0M
Change in diluted share count1.3%0.3%
Last close$942.04$61.42
P/E at the last close——
Insider trades, last 12 months—sold $4.6 million
Piotroski F-score—5 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
argenxBioMarin Pharmaceutical
Operating margin
Percent of revenue
argenxBioMarin Pharmaceutical
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
argenxBioMarin Pharmaceutical

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the argenx and BioMarin Pharmaceutical pages.